These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22104755)

  • 21. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use.
    Rozen P; Comaneshter D; Levi Z; Hazazi R; Vilkin A; Maoz E; Birkenfeld S; Niv Y
    Cancer; 2010 May; 116(9):2115-25. PubMed ID: 20186820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fecal Occult Blood Tests in Colorectal Cancer Screening: Systematic Review and Meta-analysis of Traditional and New-generation Fecal Immunochemical Tests.
    Meklin J; SyrjÄnen K; Eskelinen M
    Anticancer Res; 2020 Jul; 40(7):3591-3604. PubMed ID: 32620599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer Care Ontario guaiac fecal occult blood test (FOBT) laboratory standards: evidentiary base and recommendations.
    Rabeneck L; Zwaal C; Goodman JH; Mai V; Zamkanei M
    Clin Biochem; 2008 Nov; 41(16-17):1289-305. PubMed ID: 18796300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of fecal occult blood tests for colorectal cancer screening in an Alaska Native population with high prevalence of Helicobacter pylori infection, 2008-2012.
    Redwood D; Provost E; Asay E; Roberts D; Haverkamp D; Perdue D; Bruce MG; Sacco F; Espey D
    Prev Chronic Dis; 2014 Apr; 11():E56. PubMed ID: 24721216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Noninvasive testing for colorectal cancer: a review.
    Ouyang DL; Chen JJ; Getzenberg RH; Schoen RE
    Am J Gastroenterol; 2005 Jun; 100(6):1393-403. PubMed ID: 15929776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies in screening for colon carcinoma.
    de Wijkerslooth TR; Bossuyt PM; Dekker E
    Neth J Med; 2011 Mar; 69(3):112-9. PubMed ID: 21444935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
    Dollinger MM; Behl S; Fleig WE
    Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial.
    Hoffman RM; Steel S; Yee EF; Massie L; Schrader RM; Murata GH
    Prev Med; 2010; 50(5-6):297-9. PubMed ID: 20307568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA methylation of phosphatase and actin regulator 3 detects colorectal cancer in stool and complements FIT.
    Bosch LJ; Oort FA; Neerincx M; Khalid-de Bakker CA; Terhaar sive Droste JS; Melotte V; Jonkers DM; Masclee AA; Mongera S; Grooteclaes M; Louwagie J; van Criekinge W; Coupé VM; Mulder CJ; van Engeland M; Carvalho B; Meijer GA
    Cancer Prev Res (Phila); 2012 Mar; 5(3):464-72. PubMed ID: 22135045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Noninvasive screening tests for colorectal cancer.
    Imperiale TF
    Dig Dis; 2012; 30 Suppl 2():16-26. PubMed ID: 23207928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Replacing the Guaiac Fecal Occult Blood Test With the Fecal Immunochemical Test Increases Proportion of Individuals Screened in a Large Healthcare Setting.
    Akram A; Juang D; Bustamante R; Liu L; Earles A; Ho SB; Wang-Rodriguez J; Allison JE; Gupta S
    Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1265-1270.e1. PubMed ID: 28167157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fecal occult blood testing.
    Sanford KW; McPherson RA
    Clin Lab Med; 2009 Sep; 29(3):523-41. PubMed ID: 19840685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data].
    Ewald N; Toepler M; Akinci A; Kloer HU; Bretzel RG; Hardt PD
    Z Gastroenterol; 2005 Dec; 43(12):1313-7. PubMed ID: 16315127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sex differences in performance of fecal occult blood testing.
    Brenner H; Haug U; Hundt S
    Am J Gastroenterol; 2010 Nov; 105(11):2457-64. PubMed ID: 20700114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Colon cancer screening strategies.
    Agrawal J; Syngal S
    Curr Opin Gastroenterol; 2005 Jan; 21(1):59-63. PubMed ID: 15687886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New immunochemical fecal occult blood test with two-consecutive stool sample testing is a cost-effective approach for colon cancer screening: results of a prospective multicenter study in Chinese patients.
    Li S; Wang H; Hu J; Li N; Liu Y; Wu Z; Zheng Y; Wang H; Wu K; Ye H; Rao J
    Int J Cancer; 2006 Jun; 118(12):3078-83. PubMed ID: 16425283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
    van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
    Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High sensitivity of five colorectal screening programmes with faecal immunochemical test in the Veneto Region, Italy.
    Zorzi M; Fedato C; Grazzini G; Stocco FC; Banovich F; Bortoli A; Cazzola L; Montaguti A; Moretto T; Zappa M; Vettorazzi M
    Gut; 2011 Jul; 60(7):944-9. PubMed ID: 21193461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper.
    Duffy MJ; van Rossum LG; van Turenhout ST; Malminiemi O; Sturgeon C; Lamerz R; Nicolini A; Haglund C; Holubec L; Fraser CG; Halloran SP
    Int J Cancer; 2011 Jan; 128(1):3-11. PubMed ID: 20824704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
    Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
    Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.